Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Francesca Spada, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses updates in neuroendocrine neoplasms at the European Society for Medical Oncology (ESMO) 2026 Congress, highlighting the evolution of…
In this Grand Rounds in Urology presentation, Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD, Urology and Pelvic Floor Nurse Specialist, University of Pennsylvania; Adjunct Professor of Surgery,…
Anthony “John” Adrian Bryan was confident in his decision to receive cancer treatment at UT MD Anderson, even though he was diagnosed with a rare bladder cancer. “Medicine…
James P. Allison, Ph.D., regental professor and chair of Immunology, and vice president and founding director of the James P. Allison Institute™, recently banged the gong after completing…
Alberto Puccini, MD, Humanitas Research Hospital, Rozzano, Italy, discusses the limitations of TNM staging in resected colon cancer and outlines emerging biomarkers and technologies to improve patient prognostication…
Alberto Puccini, MD, Humanitas Research Hospital, Rozzano, Italy, comments on the clinical integration of MMR and MSI status in colon cancer management, highlighting its multifaceted role as a…
Alberto Puccini, MD, Humanitas Research Hospital, Rozzano, Italy, discusses the evolving landscape of immunotherapy in the neoadjuvant setting for colorectal cancer, acknowledging ongoing debate regarding optimal treatment strategies…
Jaafar Bennouna, MD, Foch Hospital, Suresnes, France, advocates for a shift from adjuvant to neoadjuvant treatment strategies, even in microsatellite-stable (MSS) colon cancer, noting that while immunotherapy is…
Kaissa Ouali, MD, Institut Gustave Roussy, Villejuif, France, describes long-term overall survival with NI-1801, a mesothelin x CD47 bispecific antibody, as monotherapy and in combination with pembrolizumab in…
Jean-Pascal Machiels, MD, Cliniques Universitaires Saint-Luc, Brussels, Belgium, discusses a retrospective circulating tumor DNA (ctDNA) analysis from the Phase III KEYNOTE-412 (NCT03040999) trial of pembrolizumab or placebo plus…